Allogene Therapeutics, Inc. Profile Avatar - Palmy Investing

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimer…

Biotechnology
US, South San Francisco [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Allogene Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ALLO's Analysis
CIK: 1737287 CUSIP: 019770106 ISIN: US0197701065 LEI: - UEI: -
Secondary Listings
ALLO has no secondary listings inside our databases.